medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

1

DNA methylation biomarker in blood predicts frailty

2

in an HIV-positive veteran population

3
4

Chang Shu1,2, Amy C. Justice1,2, Xinyu Zhang1,2, Vincent C. Marconi3, Dana B.

5

Hancock4, Eric O. Johnson4,5, Ke Xu1,2

6

1. Department of Psychiatry, Yale School of Medicine, New Haven, CT, 06516

7

2. Connecticut Veteran Healthcare System, West Haven, CT, 06515

8

3. Division of Infectious Disease, Emory University School of Medicine, Atlanta GA

9

4. Center for Omics Discovery and Epidemiology, Behavioral Health Research Division,

10

RTI International, Research Triangle Park, NC, USA

11

5. Fellow Program, RTI International, Research Triangle Park, NC, USA.

12
13

All corresponding address to

14

Ke Xu, M.D., Ph.D.

15

Associate Professor of Psychiatry

16

Yale School of Medicine

17

Email: ke.xu@yale.edu

18

Tel: 203-932-5711x7430

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

19

Abstract

20

Background: With the improved life expectancy in people living with HIV, predicting

21

individual frailty is important for clinical care. DNA methylation (DNAm) has emerged as

22

a robust biomarker in precision medicine and has been previously linked to aging and

23

mortality in non-HIV populations. Here, we aim to establish a panel of DNAm features

24

selected from blood methylome to predict frailty in HIV-positive men from a veteran

25

population, Veterans Aging Cohort Study (VACS).

26

Methods: We used a well-established score, VACS Index, as a measure of frailty.

27

Samples (ntotal=1,150) were divided into a training set (n=612) and a validation set

28

(n=538). We first selected a panel of frailty-associated CpGs by conducting an

29

epigenome-wide association analysis on the VACS index in the training set. We then

30

applied four machine learning methods to build models to predict high and low frailty

31

individuals in the training set. The prediction models were tested in the validation set. A

32

methylation score constructed from the selected CpGs was tested an associated with

33

mortality by performing survival analysis. To assess the biological relevance of the

34

selected CpG sites, we performed a gene ontology enrichment analysis.

35

Results: A panel of 119 CpGs were identified from the training set (False Discovery

36

Rate <0.2) that showed excellent performance on predicting high frailty individuals with

37

Area Under Curve (AUC) of 0.835 (95%CI: 0.792, 0.879) and balanced accuracy of

38

0.693. The same panel showed good performance on predicting low frailty individuals

39

with AUC of 0.735 (95%CI: 0.688-0.782) and a balanced accuracy of 0.528. The

40

methylation score from the 119 CpGs was significantly associated with 5-year and 10-

41

year mortality with hazard ratio of 1.40 (95% CI:1.033, 1.897 p=0.03) and 1.48 (95%CI:

2

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

42

1.10, 2.02; p=0.01) respectively. These 119 CpGs were located within or near 73 genes

43

that were significantly enriched in 9 biological pathways relevant to immune and

44

inflammation response.

45

Conclusions: We identified a panel of predictive DNAm features associated with frailty

46

and mortality among HIV-positive population. These DNAm features may serve as

47

biomarkers to discriminate high and low frailty people who live with HIV.

48
49

Keywords: DNA methylation, HIV-positive, frailty, mortality, DNA methylation score,

50

machine learning prediction

51
52

3

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

53
54

Background
Combination antiretroviral therapy has significantly improved life expectancy

55

among HIV-positive individuals. The prolonged life expectancy increases frailty risk in

56

the HIV population. The prevalence of frailty in people living with HIV is significantly

57

higher and onset of frailty occurs at an earlier age compared to the general population

58

(1). High frailty is characterized by marked vulnerability and is associated with increased

59

mortality. Thus, prediction of frailty is important to identify vulnerable group and deliver

60

clinical care to highly vulnerable HIV-positive patients. At present, frailty is usually

61

defined by clinical symptoms (e.g., Fried's frailty phenotype, Rockwood and Mitnitski's

62

Frailty Index) or a combination of lab tests that indicate organ damage such as the

63

Veterans Aging Cohort Study index (VACS index) (2). No biomarkers available to

64

capture the early stage of the frailty to predict individual vulnerability in HIV-positive

65

patients.

66

A large body of evidence has demonstrated that epigenetic modification adapts

67

internal and external environmental changes and that is associated with early stage of

68

pathophysiological processes (3-6). DNAm, one type of the most widely studied

69

epigenetic marks, is strongly related with aging (7-9), substance use (e.g. cigarette

70

smoking and alcohol consumption) (10-16), and a variety of diseases (3-6, 17, 18).

71

Because DNAm is relatively stable and easy to detect from body fluids biospecimen

72

through non-invasive procedure, DNAm marks have emerged as robust biomarkers for

73

cancer diagnosis (19), disease subtype classification (20, 21) and treatment response

74

monitoring (22, 23).

4

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

75

DNAm may play an important role in frailty among HIV-positive individuals. Frailty

76

is associated with elevated inflammation markers such as IL-6 and hsCRP in HIV-

77

positive individuals (24). Genes involved in immune and inflammation processes are

78

also subject to epigenetic modification in immune cells. We previously reported

79

association of two CpG sites in the promoter region of NLRC5 with HIV infection (25),

80

and NLRC5 gene is a major transcriptional activator of MHC class I gene. DNAm was

81

also linked to HIV comorbid medical diseases such as HIV-positive diabetes and kidney

82

function (26, 27). Furthermore, aging, a critical contributor to frailty, is significantly

83

associated with thousands of CpGs in the epigenome, and the epigenetic clock and

84

DNAm age are becoming widely recognized (7-9). DNAm age is significantly correlated

85

with physical frailty in HIV-negative individuals (28) and HIV-positive individuals (29). In

86

HIV-positive individuals, the average DNAm age is accelerated 5 to 10 years faster than

87

HIV-negative individuals (30-33) and 10 years faster in the HIV-positive frailty

88

individuals in comparing to HIV-positive non-frailty individuals (29). These age-related

89

DNAm signatures are predictive of mortality (34-38). Additional CpGs in blood have

90

been identified to predict all-cause mortality (34, 39). Therefore, we hypothesize that

91

DNAm is associated with frailty and that DNAm signatures in blood can serve as

92

biomarkers to predict frailty and mortality among HIV-positive individuals.

93

In this study, our goal is to identify DNAm marks that can serve as biomarkers

94

on frailty and to link frailty-associated DNAm to mortality among HIV-positive

95

individuals. We also evaluated biological relevance of the identified CpG sites. We used

96

a well-established frailty score, VACS index, as a measure of frailty in the HIV-positive

97

population. The VACS index is a composite score constructed by a sum of pre-assigned

5

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

98

points on age, CD4 count, HIV-1 RNA, hemoglobin, platelets, aspartate and alanine

99

transaminase (AST and ALT), creatine, estimated glomerular filtration rate (eGFR), and

100

viral hepatitis C infection (40). Findings from this study provide a set of DNAm

101

biomarkers to predict frailty for future clinic use and new insights into the epigenetic

102

mechanism of frailty and mortality in HIV pathology.

103
104
105

Methods
As an overview, our analytical procedure is shown in the flowchart in Figure 1.

106

Our sample was divided into the training set (n=612) and the validation set (n=538)

107

which DNA methylation were processed at different time and using two different

108

platforms. We first selected a panel of CpG sites relevant to frailty based on EWAS

109

results in the training set. Then, we applied four commonly used machine learning

110

classification methods to develop prediction models: random forest, Extreme Gradient

111

Boosting Tree (XGBoost), Lasso and Elastic-Net Regularized Generalized Linear

112

Models (GLMNET), and Support Vector Machines (SVM). The selected CpG sites were

113

used as predictors to differentiate high and low frailty in the training set and each model

114

was evaluated in the validation set. Additionally, the DNAm score was constructed

115

based on the selected CpG sites and we conducted survival analysis to assess whether

116

the DNAm score was associated with mortality in the HIV-positive samples. Lastly, we

117

conducted a gene ontology enrichment analysis to reveal the underlying biological

118

pathways of the selected CpG sites.

119

Study population

6

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

120

All samples in the training and validating sets were from the VACS cohort. The

121

VACS is a prospective cohort study of veterans focusing on clinical outcomes in HIV

122

infection (41). DNA samples were extracted from peripheral blood of 1,150 HIV-positive

123

men from the VACS. Demographic and clinical information on age, race, smoking

124

status, CD4 count, viral load, HIV medication adherence, VACS index, and mortality by

125

training set and validation set are presented in Table 1. The training set included slightly

126

older individuals, more African Americans, and greater VACS index than the validation

127

set. There was no significant difference in HIV medication adherence, CD4 count, or

128

log10 HIV-1 viral load between the training set and the validation set.

129

Table 1: Study sample characteristics
Training set
Validation set
(N=612)
(N=538)
p value*
Age (year, mean +/-sd)
49.4 (7.6)
48.1 (7.8)
0.005
Male (%)
612 (100)
538 (100)
Race (%)
Caucasian
58 (9.5)
48 (8.9)
0.001
African Americans
526 (85.9)
435 (80.9)
Other
28 (4.6)
55 (10.2)
Smokers (%)
360 (59.4)
309 (58.4)
0.78
HIV positive (%)
614 (100)
538 (100.0)
HIV treatment adherence
(%)
469 (78.4)
407 (76.6)
0.519
CD4 count
428.97 (286.33)
447.46 (279.27)
0.287
log 10 HIV-1 viral load
2.61 (1.19)
2.67 (1.23)
0.423
VACS index (mean +/-)
35.64 (21.99)
30.78 (20.23)
<0.001
Mortality (%)
162 (26.5)
129 (24.0)
0.367
*t test is used for continous variables, chi-square test is used for categorical variables

130

Genome-wide DNAm profiling and quality control

131

The DNA samples in the training set were profiled by Infinium Human Methylation 450K

132

BeadChip (HM450K) and the DNA samples in the validation set were profiled by the

7

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

133

Infinium Human Methylation EPIC BeadChip. DNAm for the training and validation sets

134

were evaluated using the same quality control (QC) protocol (42) in the R package minfi

135

(43). In detail, CpG sites on sex chromosomes and within 10 base pairs of a single

136

nucleotide polymorphism were removed. The detection p-value threshold was set at 10-

137

12

138

HM450K and EPIC arrays were used for analysis to ensure the same coverage

139

between two sets. Proportions of 6 cell types (CD4+ T cells, CD8+ T cells, Natural Killer

140

T cells, B cells, monocytes and granulocytes) were estimated using the established

141

method (Houseman et al., 2012) for all samples in the training and validation sets.

142

Selection of CpG sites from EWAS on frailty in the training set

143

for both the training and validation sets. After QC, 408,583 shared CpG sites between

We performed an EWAS on VACS index in the training set using a two-step

144

linear model approach as previously described (42). The analytical model was adjusted

145

for systematic errors and clinical confounding factors. Here, log transformation was

146

applied to VACS index to ensure normality distribution assumption for the linear model.

147

First, the following linear model was used to extract principal components (PCs)

148

for potential confounding variables. Here, top 30 control PCs were derived from internal

149

control probes in minfi:

150

Methylation Î² ~ age + race + smoking + self-reported HIV medication adherence

151

+ log viral load + WBC + CD4T + CD8T + Gran + NK + B cell + Mono + 30 Control PCs

152

Second, the top 20 residual PCs were extracted in the model above to fully

153

adjust for unmeasured confounding. The final EWAS model on VACS index was:

8

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

154

log(VACS) ~ Methylation Î² + age + race + smoking + self-reported HIV

155

medication adherence + log viral load + WBC + CD4T + CD8T + Gran + NK + B cell +

156

Mono + 30 Control PCs + 20 Residual PCs

157

To ensure a sufficient number of CpGs as predictors for the prediction model

158

development, we selected CpG sites with false discovery rate (FDR) <0.2 in the EWAS

159

as predictors.

160

Additionally, to explore the underlying epigenetic mechanism of frailty, we also

161

detected differentially methylated regions (DMRs) using bumpHunter (44) in the training

162

set. DMRs with family-wise error rate (FWER)<0.2, which is equivalent to FDR<0.03,

163

were considered significant.

164

Developing machine learning prediction models for frailty

165

Based on the distribution of the VACS index in the entire sample (Figure S1) and

166

clinical significance (45), high HIV frailty was defined as VACS index > 50, and low HIV

167

frailty was defined as VACS index < 16. Models were developed to predict high frailty

168

(VACS index >50 versus â©½50) and low frailty (VACS index <16 versus â‰¥16). CpGs

169

relevant to frailty were selected from EWAS as described above. The following steps

170

were taken to develop separate prediction models on high and low frailty:

171

1) Model development in the training set: Four machine learning models, random

172

forest, Extreme Gradient Boosting Tree (XGBoost), support vector machines(SVM),

173

Lasso and Elastic-Net Regularized Generalized Linear Models (GLMNET), were

174

separately applied to predict VACS index by using the R package caret (46). These four

175

models are commonly used in the supervised learning on classification (47-50). Each

9

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

176

model was developed separately and 10-fold cross-validation was used in model

177

training process to minimize data overfitting.

178

2) Model evaluation in the validation set: All four models built in the training set

179

were evaluated in the validation set. Area Under Curve (AUC) and balanced accuracy

180

were used to assess the prediction performance. We used balanced accuracy for model

181

evaluation because in the presence of imbalance samples in each class since there are

182

228 subjects with VACS index greater than or equal to 50 and 916 subjects with VACS

183

index less than 916. Balanced accuracy is defined as the average accuracy obtained on

184

each class as shown in the following formula (51). Balanced accuracy was used in this

185

study to avoid biased accuracy due to imbalanced samples (51).

186
187
188
189
190

ğµğµğµğµğµğµğµğµğµğµğµğµğµğµğµğµ ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘
=

ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›
1
ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘
+
2 ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘¡ğ‘¡ğ‘–ğ‘–ğ‘–ğ‘–ğ‘–ğ‘– + ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘› ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ğ‘‡ ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘›ğ‘› + ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ğ¹ ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘

Association of a DNAm score for VACS index with mortality

191

We constructed a DNAm score by the selected frailty-associated CpG sites. A

192

survival analysis was conducted to assess whether the DNAm score was associated

193

with 5-year and 10-year mortality respectively.

194
195
196
197

DNAm score was constructed based on a previously reported method (12). We
computed the DNAm score by normalizing the score with mean ğ›½ğ›½ value (ğœ‡ğœ‡< ) and

standard deviation, ğœğœ< , from subjects with VACS index <50 (control group). For selected

ğ‘›ğ‘› methylation sites, ğ‘Šğ‘Š< is 1 for a hypermethylated methylation site ğ‘ğ‘, and -1 for a

10

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

198
199
200
201
202
203

hypomethylated site ğ‘ğ‘, ğ›½ğ›½<? is the ğ›½ğ›½ value for subject ğ‘–ğ‘– and methylation site ğ‘ğ‘. The
methylation score for subject ğ‘–ğ‘– was constructed by the following formula:
1
ğ‘€ğ‘€ğ‘€ğ‘€ğ‘¡ğ‘¡â„ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†ğ‘†? =
ğ‘›ğ‘›

D

<EF

ğ‘Šğ‘Š<

ğ›½ğ›½<? âˆ’ ğœ‡ğœ‡<
ğœğœ<

The mean methylation score was 0, and samples were divided into high
methylation score (>0) and low methylation score (â©½0) groups.
We preformed Kaplan-Meier survival curves during 10-year follow-up to visualize

204

the survival differences between high and low methylation score groups. Survival

205

analysis was conducted by cox proportional hazards model on 5-year and 10-year

206

mortality comparing high and low methylation groups. We used age as time scale t, and

207

our model was adjusted for race, smoking, self-reported HIV medication adherence, log

208

10 of HIV viral load and CD4 count.

209
210
211
212
213
214

â„ ğ‘¡ğ‘¡ = â„G (ğ‘¡ğ‘¡)exp (ğ›½ğ›½F ğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šâ„ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ğ‘¦ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘  + ğ›½ğ›½N ğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿğ‘Ÿ + ğ›½ğ›½O ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ 

+ ğ›½ğ›½Q ğ»ğ»ğ»ğ»ğ»ğ» ğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘š ğ‘ğ‘ğ‘ğ‘â„ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ğ‘’ + ğ›½ğ›½U logFG ğ‘£ğ‘£ğ‘£ğ‘£ğ‘£ğ‘£ğ‘£ğ‘£ğ‘£ğ‘£ ğ‘™ğ‘™ğ‘™ğ‘™ğ‘™ğ‘™ğ‘™ğ‘™ + ğ›½ğ›½Y ğ¶ğ¶ğ¶ğ¶4 ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘)

Biological interpretation of the predictive panel of CpG sites on frailty
We performed gene ontology (GO) enrichment analysis using Database for

215

Annotation, Visualization and Integrated Discovery (DAVID) (52). To avoid redundancy

216

in pathway names, we only used level 4 GO terms defined in DAVID in the enrichment

217

analysis. Genes with at least one frailty-associated CpG site was used for GO analysis.

218

We considered biological pathways with FDR <0.05 as statically significant pathways.

219

11

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

220

Results

221

Selection a panel of 119 frailty-associated CpG sites by EWAS in the training set

222

In the training set, we conducted an EWAS on VACS index (Figure 2; Î»=1.038) and

223

selected 119 CpGs with FDR<0.2 to ensure sufficient number of predictors (Table 2).

224

Eighty out of 119 CpGs were negatively associated with VACS index, while 39 out of

225

119 CpGs were positively associated with VACS index. The majority of CpGs were

226

located within or near known genes, except for 19 CpGs that were intergenic. Only 40

227

CpGs were located in gene bodies, while 79 CpGs were located in promoter regions,

228

first exons, or 3â€™ UTR. Thirty-two CpGs were located in CpG islands.

229

Notably, 22 out of 119 CpGs reached epigenome-wide significance (FDR<0.05),

230

including 16 CpG sites negatively associated with the VACS index and 6 CpG sites with

231

positive associations. These 22 CpGs were located on 17 genes, including 13 of 22

232

CpGs located in promoter regions, 6 CpGs in gene body, and 3 CpGs in 3â€™UTR. Among

233

these genes, some harbored more than one significant CpG. For example, three CpGs

234

were annotated within or near PSMB8 (cg01309328, p=4.44Ã—10-9; cg08099136,

235

p=4.63Ã—10-9; cg00533183, p=3.18Ã—10-7), two CpGs were located near PARP9

236

(cg08122652, p=2.18Ã—10-7; cg22930808, p=6.78Ã—10-7), two CpG sites were located

237

near IFITM1 (cg03038262, p=5.83Ã—10-7; cg23570810, p=1.58Ã—10-6), and the rest of the

238

significant CpG sites were annotated to 13 genes including MX1, TAP1, ZNF32,

239

NLRC5, IFI44L.

240

We found 9 significant DMRs in the training set (Table S1). Methylation Î² values

241

between high and low frailty ranged from -0.15 to 0.05 in these regions. As examples, 3

12

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

242

region plots showing DMRs in the MX1, PARP9, and IFI44L genes are shown in Figure

243

3.

244

Machine learning prediction on frailty by the selected 119 CpGs

Table 3: Performance of machine learning model predicting frailty in an HIV-infected population
High frailty (VACS index >50 vs. â‰¤50)
Low frailty (VACS index >16 vs. â‰¤16)
Training
Validation
Training
Validation
AUC

Balanced
Accuracy

AUC

Balanced
Accuracy

AUC

Balanced
Accuracy

AUC

Balanced
Accuracy

0.775

0.622

0.835 (0.792,0.879)

0.693

0.774

0.509

0.735 (0.688,0.782)

0.528

XGBoost

0.760

0.624

0.830 (0.786,0.874)

0.684

0.820

0.637

0.716 (0.669,0.762)

0.500

GLMNET

0.783

0.642

0.757 (0.701,0.813)

0.668

0.795

0.589

0.715 (0.667,0.763)

0.503

SVM
0.759
0.618
0.744 (0.685,0.802)
0.500
0.756
AUC: Area Under Curve
VACS: Veteran Aging Cohort Study
XGBoost: Extreme Gradient Boosting Tree
GLMNET: Lasso and Elastic-Net Regularized Generalized Linear Models
SVM: Support Vector Machines
245

0.594

0.501 (0.442,0.560)

0.492

Method
Random
Forest

246

In the training set, we developed our prediction models based on the selected

247

119 CpGs in the training set using four commonly used machine learning classification

248

models: XGBoost, random forest, SVM and GLMNET (47-50). Performances of four

249

prediction models are presented in Table 3. We found that AUCs ranged from 0.756 to

250

0.820 and balanced accuracies ranged from 0.509 to 0.642, suggesting that the 119

251

CpGs had good to excellent predictive performance on frailty. The performances of four

252

models were mostly comparable. For predicting high frailty, GLMNET outperformed the

253

three other models (AUC=0.783, balanced accuracy=0.642) while SVM performed

254

slightly worse (AUC=0.759, balanced accuracy = 0.618). For the prediction of low frailty,

13

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

255

XGBoost performed the best among the four models (AUC=0.820, balanced

256

accuracy=0.637) while SVM performed worst (AUC=0.756, balanced accuracy =0.594).

257

In the validation set, for the prediction of high frailty, random forest and XGBoost

258

showed the best performance. AUC of random forest model was 0.835 (95%CI: 0.792,

259

0.879) and XGBoost was 0.830 (95%CI: 0.786, 0.874) for predicting high frailty.

260

Balanced accuracy was 0.69 and 0.68, respectively, for random forest and XGBoost

261

(Figure 4). For the prediction of low frailty, XGBoost and random forest models also

262

outperformed GLMNET and SVM. AUC was 0.735 (95%CI: 0.688, 0.782) for the

263

random forest and 0.716 (95%CI: 0.669, 0762) for the XGBoost. The balanced accuracy

264

was 0.528 and 0.500 for the random forest and XGBoost, respectively.

265

These results suggest that the selected panel of 119 CpG sites were able to

266

predict frailty, and the prediction models performed better at predicting high frailty than

267

predicting low frailty. Among four machine learning methods, SVM showed poor

268

performance of predicting frailty in our samples.

269
270
271

DNAm score by 119 CpGs was significant associated with mortality
We constructed DNAm score based on the selected 119 CpGs, and we further

272

assessed whether VACS index-related DNAm score were associated with mortality. In

273

Figure 5, the Kaplan Meier curves during 10-year follow-up showed that the individuals

274

with high DNAm score were at higher risk of mortality than those with low DNAm

275

scores. After adjusting for confounding factors, our cox proportional hazards regression

276

model showed that the hazard ratio of 5-year and 10-year mortality comparing high and

277

low DNAm score groups were 1.40 (95%CI: 1.03-1.90, p=0.03) and 1.48 (95%CI: 1.10-

14

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

278

2.02, p=0.01) respectively. In conclusion, we found that the DNAm score constructed

279

from the 119 selected CpGs was significantly associated with mortality.

280

Biological interpretations of 119 CpGs by gene ontology enrichment analysis
The selected panel of 119 CpGs were located within or near 73 genes. Gene

281
282

ontology enrichment analysis using these 73 genes resulted in 9 significant pathways

283

with FDR<0.05 (Figure 6, Table 4). These pathways included response to type I

284

interferon response (FDR=1.05Ã—10-7), innate immune response (FDR=3.45Ã—10-5),

285

cytokine response (FDR=3.69Ã—10-3) and defense response to virus (Figure 6). Our

286

findings suggested that the selected 119 CpG sites are biologically relevant to HIV

287

pathogenesis and progression.
Table 4: Gene ontology term enrichment analysis of the selected CpG sites that predict frailty in an HIV
infected population
Term

N

%

GO:0034340~response to type
I interferon

10

11.8

GO:0045087~innate immune
response

19

22.4

GO:0051607~defense
response to virus

11

12.9

GO:0051707~response to
other organism

18

21.2

Genes
OAS2, IFITM1, IFIT3,
MX1, NLRC5, HLA-F,
XAF1, HLA-E, IRF7,
PSMB8
TRIM22, MAP4K2,
IFITM1, TRIM25,
MX1, GFI1, IFIT5,
XAF1, LY86, PSMB8,
TRIM14, PARP9,
PLSCR1, OAS2, IFIT3,
NLRC5, HLA-F, HLA-E,
IRF7
TRIM22, PLSCR1,
OAS2, IFITM1,
TRIM25, IFIT3, MX1,
IFI44L, NLRC5, IFIT5,
IRF7
TRIM22, PDE4B, EPO,
IFITM1, NOTCH1,
TRIM25, MX1, GFI1,
IFIT5, IFI44L, LY86,
PLSCR1, OAS2, IFIT3,

Fold
Enrichment

P value

FDR

28.1

6.62E-11

1.05E-07

5.0

2.17E-08

3.45E-05

10.5

7.55E-08

1.20E-04

4.8

1.17E-07

1.85E-04

15

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

CCDC88B, NLRC5,
HLA-E, IRF7

GO:0016032~viral process

19

22.4

GO:0009615~response to
virus

11

12.9

GO:0098542~defense
response to other organism

13

15.3

GO:0034097~response to
cytokine

16

18.8

GO:0034341~response to
interferon-gamma

8

9.4

288
289

TRIM22, IFITM1,
TFRC, NOTCH1,
TRIM25, MX1, PPIB,
GFI1, IFIT5, IFI44L,
TAP1, PSMB8,
TRIM14, PLSCR1,
OAS2, SLC1A5, IFIT3,
NLRC5, IRF7
TRIM22, PLSCR1,
OAS2, IFITM1,
TRIM25, IFIT3, MX1,
IFI44L, NLRC5, IFIT5,
IRF7
TRIM22, PLSCR1,
OAS2, IFITM1,
TRIM25, IFIT3, MX1,
CCDC88B, IFIT5,
NLRC5, IFI44L, HLA-E,
IRF7
TRIM22, EPO,
IFITM1, TRIM25,
MX1, GFI1, XAF1,
PSMB8, PARP9,
PLSCR1, OAS2, IFIT3,
NLRC5, HLA-F, HLA-E,
IRF7
TRIM22, OAS2,
IFITM1, TRIM25,
NLRC5, HLA-F, HLA-E,
IRF7

4.3

1.93E-07

3.07E-04

7.7

1.27E-06

2.02E-03

5.8

1.94E-06

3.09E-03

4.4

2.32E-06

3.69E-03

10.9

7.95E-06

1.26E-02

Discussion

290

In this study, we present evidences that DNAm marks in blood are predictive of

291

frailty and are associated mortality in an HIV-positive population. We identified a panel

292

of 119 CpG sites that were highly predictive for high frailty and moderately predictive for

293

low frailty. We also found that the DNAm score constructed by these 119 CpGs was

294

strongly associated with mortality in the HIV-positive population. More importantly, these

16

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

295

clinically informative 119 DNAm features lied in genes involved in HIV pathogenesis and

296

progression. Thus, we discovered a panel of 119 DNAm biomarkers that add knowledge

297

to the epigenetic mechanisms underlying frailty and mortality among people living with

298

HIV.

299

We demonstrated the utility of using DNAm marks to predict frailty in HIV-positive

300

individuals. We took the several steps to avoid overfitting in developing the prediction

301

models: 1) model development and evaluation were conducted separately in training set

302

and validation set. DNAm in two sets were profiled in different time with different

303

platforms; 2) 10-fold cross validation were performed during training in each model. The

304

performances of four machine learning methods were in general consistent except that

305

the SVM did not perform well for low frailty. Our results suggested that this panel of

306

CpG sites was relatively stable and robust although performances of predictive models

307

differed using different methods. Of note, SVM showed the worst performance in

308

predicting high and low frailty that highlights the importance of choosing appropriate

309

machine learning method for model development. Compared to our previously reported

310

a panel of 698 smoking-associated CpGs that are moderately predictive of frailty (15),

311

the panel of 119 CpG sites in the present study includes fewer CpGs (119 CpGs) and

312

shows greater prediction performance on frailty (AUC=0.73 for smoking-associated

313

CpGs and AUC 0.83 for the VACS index-associated CpGs), suggesting that the panel

314

of 119 CpG sites has greater clinical utility for frailty among people living with HIV. The

315

improvement of prediction performance on frailty in the present study may be due to

316

different strategies of CpG selections. In this study, the 119 CpGs are selected from the

17

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

317

entire blood methylome and may be more informative than the smoking-associated

318

CpGs in our previous report.

319

We also found that the VACS index-related DNAm score derived from the 119

320

CpGs is strongly associated with mortality. This result provides further knowledge of

321

epigenetic profile into previous report that VACS index is predictive of mortality in

322

people who live with HIV (53). The result is also consistent with previous literature

323

showing that DNAm marks in blood predict mortality in the general population (39).

324

Interestingly, we found no overlapped CpG between our predictive panel and the

325

previously identified CpGs for all-cause mortality that included CpGs associated with a

326

variety of diseases such as diabetes and cancer(39). The discrepancy suggest that

327

methylation-based prediction of mortality may be relevant to causal disease. A recent

328

study reports a significant overlap of mortality-associated CpGs and aging-associated

329

CpGs (Lund et al, 2019). We found no overlapped CpG site between our mortality-

330

related 119 CpG panel and aging-related 353 CpGs in epigenetic clock (7), suggesting

331

that epigenetic mechanisms in HIV-related mortality differ from aging-related mortality.

332

Most importantly, this panel of 119 CpG sites are biologically meaningful and

333

may shed light on our understanding of the biological mechanisms of frailty for HIV-

334

positive individuals. The majority of the 119 CpG sites were located within or near

335

genes that are involved in known HIV pathology and progression. The results from DMR

336

analysis are corresponding to some of the significant genes for frailty. For example,

337

cg26312951, cg22862003 and cg21549285 from the 119 CpG sites are located in the

338

MX1 gene (Interferon-Induced GTP-Binding Protein Mx1) and were negatively

339

associated with frailty. A DMR on MX1 also showed a significant with frailty. MX1

18

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

340

encodes a GTP-metabolizing protein induced by interferon I and II and is involved in

341

interferon gamma signaling and Toll-like signaling pathway. Multiple CpGs near the

342

HLA-F and HLA-E genes are part of the predictive panel, and these two genes are

343

actively involved in immune response (54). Our previously reported HIV-associated

344

CpG site, cg07839457 in the NLRC5 gene is also a member of the predictive panel on

345

frailty (25). Other interesting gene regions reveled by DMR analysis include PARP9 and

346

IFI44L, which both genes are involved in HIV pathogenesis. The biological relevance of

347

these 119 CpG sites was further supported by the gene ontology enrichment analysis.

348

The top enriched pathways such as type I interferon response and cytokine response

349

may point out important biological pathways that leads to frailty and increased risk of

350

mortality among people living with HIV.

351

We acknowledge several limitations in this study. The generalizability of the

352

selected CpG sites may be limited since our samples were predominantly middle-aged

353

men, which may not generalize to frailty in a different age group. All samples in our

354

study are HIV-positive and the identified CpGs have a limited application to HIV-

355

negative population as we discussed above. Future studies in diverse populations is

356

warranted to validate the selected methylation features. Lastly, the prediction of low

357

frailty is moderate due to imbalanced sample distribution in our present study. We

358

expect that including more samples with low frailty will improve the predictive

359

performance.

360
361

Conclusions

19

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

362

We identified a panel of 119 predictive DNAm features in blood that are associated with

363

frailty and mortality among people living with HIV. These DNAm features may serve as

364

biomarkers to discriminate high and low frailty groups and may help to prioritize genes

365

to better understand the mechanisms of frailty in HIV-positive population. These DNAm

366

features have potential to serve as biomarkers to monitor HIV progression in future

367

clinical care.

368

20

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

369

Legends

370

Figure 1: Flowchart of analytical procedures on selection of CpG sites in peripheral

371

blood methylome, machine learning prediction models to predict frailty, DNA

372

methylation score to assess mortality, and gene ontology enrichment analysis

373

Figure 2: Manhattan and quantile-quantile plots on Veteran Aging Cohort Study (VACS)

374

index (Î»=1.038) in the training set; blue line indicates False Discovery Rate (FDR)=0.05

375

Figure 3: Differentially methylation regions (DMRs) are associated with frailty,

376

measured by Veteran Aging Cohort Study (VACS) index. a: MX1 regional plot showing

377

methylation beta value among subjects with VACS index > 50 and VACS index â‰¤ 50 in

378

the training set. b: IFI11L regional plot showing methylation beta value among subjects

379

with VACS index > 50 and VACS index â‰¤ 50 in the training set. c: PARP9 regional plot

380

showing methylation beta value among subjects with VACS index > 50 and VACS index

381

â‰¤ 50 in the training set

382

Figure 4: Receiver operating characteristic curve by XGBoost prediction model on HIV

383

frailty; a) Predicting high HIV frailty (VACS index >50 vs. â‰¤50), Area Under Curve

384

(AUC): 0.830 (95% CI: 0.786,0.874); b) Predicting low HIV frailty (VACS index >16 vs.

385

â‰¤16), AUC: 0.735 (95% CI: 0.688,0.782)

386

Figure 5: Kaplan-Meier curves comparing high and low HIV frailty methylation score

387

groups. Methylation score is calculated by 119 selected probes. High methylation score

388

group has methylation score >=0, while low methylation score group <0.

389

Figure 6: Gene ontology enrichment analysis of 119 CpG probes (FDR<0.05) for

390

prediction

21

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

391

Figure S1: Distribution of Veteran Aging Cohort Study index (VACS index) between

392

training set and testing set

393
394

Table 1: Study sample characteristics

395

Table 2: A panel of 119 CpG sites in blood that predicts high and low frailty in a HIV-

396

positive veteran population

397

Table 3: Performance of machine learning model predicting high and low frailty in an

398

HIV-positive population

399

Table 4: Gene ontology term enrichment analysis of the selected 119 CpG sites that

400

predict frailty in an HIV-positive population

401

Table S1: Differentially methylated regions between high and low frailty in training set

402

22

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 2: A panel of 119 CpG sites in blood that predicts high and low frailty in a HIVinfected veteran population
Relation
Effect
CpG
Chr
Position
Gene
Gene group
to CpG
SE
size
Island
cg01309328
6
32811253 PSMB8
Body
N_Shore -5.30
0.888

P value

FDR*

4.44E-09

9.32E-04

cg08099136

6

32811251

PSMB8

Body

N_Shore

-4.77

0.800

4.63E-09

9.32E-04

cg26312951

21

42797847

MX1

TSS200;5UTR

N_Shore

-2.46

0.417

6.40E-09

9.32E-04

cg08818207

6

TAP1

Body

N_Shore

-3.40

0.627

9.17E-08

1.00E-02

cg08122652

3

32820355
12228193
9

PARP9

5UTR;TSS1500

N_Shore

-1.79

0.341

2.18E-07

1.45E-02

cg07352001

10

44144445

ZNF32

TSS200;TSS1500

Island

2.730

2.31E-07

1.45E-02

cg07325529

6

6613762

Body

3.980

2.77E-07

1.45E-02

cg16242615

19

4059988

cg00533183

6

cg12649038

10

LY86
ZBTB7
A
PSMB8
ABLIM
1
IRF7

14.30
20.70

5UTR

Island

-6.27

1.200

2.85E-07

1.45E-02

Body

N_Shore

-5.81

1.120

3.18E-07

1.45E-02

5.03

0.973

3.32E-07

1.45E-02

cg08926253

11

32810742
11628253
4
614761

Body

Island

-2.91

0.571

4.94E-07

1.96E-02

cg03038262

11

315262

IFITM1

3UTR

N_Shore

-2.86

0.565

5.83E-07

2.12E-02

cg07839457

16

NLRC5

TSS1500

N_Shore

-1.99

0.396

6.55E-07

2.12E-02

cg22930808

3

PARP9

5UTR

N_Shore

-1.54

0.306

6.78E-07

2.12E-02

cg03607951

1

57023022
12228188
1
79085586

TSS1500

-2.00

0.398

7.41E-07

2.16E-02

cg08260450

6

34993987

IFI44L
ANKS1
A

Body

6.35

1.270

8.43E-07

2.30E-02

cg03917473

17

9.10

1.840

1.04E-06

2.67E-02

cg18234224

1

6.59

1.350

1.34E-06

3.22E-02

cg06188083

10

38764244
17291785
1
91093005

-2.02

0.414

1.40E-06

3.22E-02

cg23570810

11

315102

cg03816851

22

18324769

cg20676542

17

54991456

cg05019807

9

cg03753191

5UTR

IFIT3

Body
Body

N_Shore

-2.31

0.475

1.58E-06

3.41E-02

Body

Island

10.30

2.120

1.64E-06

3.41E-02

TSS200

Island

-3.02

0.629

2.10E-06

4.17E-02

Body

N_Shore

5.97

1.260

2.70E-06

5.07E-02

13

13941039
3
43566902

IFITM1
MICAL
3
TRIM2
5
NOTCH
1
EPSTI1

TSS1500

S_Shore

-5.39

1.140

2.88E-06

5.07E-02

cg01971407

11

313624

IFITM1

TSS1500

N_Shelf

-3.53

0.745

2.90E-06

5.07E-02

cg03359362

19

47289611

SLC1A
5

TSS1500;Body;5
UTR

N_Shore

12.60

2.670

3.13E-06

5.10E-02

cg22116398

5

196162

S_Shore

5.15

1.090

3.15E-06

5.10E-02

Body

N_Shelf

4.27

0.907

3.28E-06

5.12E-02

TSS1500

S_Shore

4.45

0.949

3.45E-06

5.20E-02

cg26922780

16

88769443

cg15748006

2

9772375

RNF16
6
YWHA
Q

23

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

cg22862003

21

42797588

MX1

TSS1500;5UTR

N_Shore

-1.66

0.356

3.88E-06

5.65E-02

cg21366673

6

30459512

Body

S_Shore

4.04E-06

5.69E-02

2

95825608

TSS1500

Island

4.220

5.25E-06

6.64E-02

cg06872964

1

79085250

-4.19
19.40
-1.92

0.900

cg05588757

HLA-E
ZNF51
4
IFI44L

0.416

5.26E-06

6.64E-02

cg06376949

10

IFIT5

TSS1500

N_Shore

-3.21

0.698

5.29E-06

6.64E-02

cg01154505

2

FBLN7

Body

S_Shore

6.16

1.340

5.32E-06

6.64E-02

cg01871595

13

91173811
11294040
9
39336304

FREM2

Body

6.90

1.500

5.59E-06

6.78E-02

cg05696877

1

79088769

5UTR

-1.21

0.265

6.01E-06

6.94E-02

cg24497541

1

55352819

cg11829870

22

50988451

cg13720750

5

cg18255813

6

11230916
7
7195966

IFI44L
DHCR2
4
KLHDC
7B

cg21549285

21

cg14945867

TSS1500

1stExon;5UTR

Island

-9.81

2.150

6.12E-06

6.94E-02

3UTR;1stExon

S_Shore

-3.63

0.795

6.28E-06

6.94E-02

N_Shelf

7.28

1.600

6.37E-06

6.94E-02

9.38

2.060

6.76E-06

6.94E-02

-1.01
29.70
-3.48

0.224

7.08E-06

6.94E-02

6.550

7.16E-06

6.94E-02

0.768

7.25E-06

6.94E-02

-6.98

1.540

7.27E-06

6.94E-02

10.90

2.410

7.31E-06

6.94E-02

6.50

1.440

7.49E-06

6.96E-02

RREB1

Body

42799141

MX1

5UTR

S_Shore

14

54908007

CNIH

1stExon

Island

cg09026253

11

313267

TSS1500

S_Shore

cg14651616

11

64563992

cg24082730

3

12607636
6

IFITM1
MAP4
K2
KLF15

TSS200

cg16302816

11

16834800

cg01765174

9

cg10552523

11

cg19025187

3

cg21081878

21

cg14299044

10

cg24871132

3

cg27294701

10088096
0
313478
19580825
5
38334730

Body
Island

PLEKH
A7
TRIM1
4
IFITM1

Body

N_Shore

-4.47

0.993

8.35E-06

7.60E-02

TSS1500

N_Shelf

-3.14

0.702

9.42E-06

8.40E-02

TFRC

5UTR

N_Shore

-6.73

1.510

1.07E-05

9.16E-02

HLCS

5UTR

N_Shelf

3.49

0.785

1.08E-05

9.16E-02

1.200

1.09E-05

9.16E-02

4.900

1.17E-05

9.55E-02

1.590

1.18E-05

9.55E-02

Body

PFN2

TSS200

Island

16

19972179
14968884
6
88107336

BANP

Body

Island

5.32
21.70
7.04

cg09296453

6

29692035

HLA-F

Body

Island

-3.24

0.735

1.31E-05

1.04E-01

cg16400434

11

73882363

PPME1
;C2CD3

TSS200;TSS1500

Island

25.60

5.850

1.46E-05

1.13E-01

cg16656286

17

4981603

TSS200

Island

22.40

5.130

1.52E-05

1.13E-01

cg26480543

19

55629279

TSS1500

S_Shore

-7.33

1.680

1.52E-05

1.13E-01

cg19371652

12

-3.59

0.822

1.52E-05

1.13E-01

cg09597638

17

11341588
3
3907349

-5.48

1.260

1.56E-05

1.14E-01

cg00994629

14

22694547

-7.44

1.710

1.62E-05

1.16E-01

ZFP3
PPP1R
12C
OAS2

TSS1500
N_Shore

24

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

cg02314339

10

91020653

cg21468416

9

12701991
4

NEK6

1stExon;TSS150
0;5UTR

N_Shore

cg12149905

3

61547208

PTPRG

TSS200

Island

cg20927242

6

29692011

Body

Island

cg03332034

16

1823786

TSS1500

Island

cg05489271

12

SETD8

Body

N_Shelf

cg25843003

6

12387169
5
31431312

HLA-F
EME2;
MRPS3
4

HCP5

3UTR

cg14090510

7

64839023

ZNF92

5UTR;Body

cg25467833

1

cg03725115

6

21233506
1
30458102

cg15620384

6

34164405

cg08450404

19

58326441

cg06927297

12

cg21684411

6

11717588
9
31431573

cg20998539

17

62208374

cg25138854

1

cg13250752

4

cg26562691

16

cg23677352

4

9555557
13828199
2
23850404
14971567
5

cg22107533

15

45028083

cg06412917

12

12485884
4

cg01190666

20

62204908

cg11977562

13

cg13304609

1

11484529
7
79085162

cg01537765

19

cg08275025

HLA-E

Body

-4.35

1.010

1.86E-05

1.29E-01

6.61

1.530

1.89E-05

1.29E-01

2.820

1.89E-05

1.29E-01

1.660

1.97E-05

1.32E-01

12.30

2.870

2.12E-05

1.36E-01

7.83

1.820

2.13E-05

1.36E-01

-3.29
14.70

0.768

2.19E-05

1.36E-01

3.440

2.21E-05

1.36E-01

4.86

1.140

2.28E-05

1.36E-01

Island

-5.09

1.190

2.29E-05

1.36E-01

Island

-6.69

1.570

2.34E-05

1.36E-01

-8.37

1.960

2.35E-05

1.36E-01

6.460

2.36E-05

1.36E-01

1.570

2.40E-05

1.36E-01

Island

ZNF55
2

TSS200

S_Shore

RNFT2

TSS200;TSS1500

Island

HCP5

3UTR

ERN1

TSS1500

PRKCB

Body

12.20
-7.14

27.60
-6.71

S_Shore

-7.32

1.720

2.42E-05

1.36E-01

Island

-7.03

1.650

2.45E-05

1.36E-01

-6.09

1.430

2.46E-05

1.36E-01

6.87

1.620

2.47E-05

1.36E-01

-7.92

1.860

2.49E-05

1.36E-01

-3.14

0.739

2.53E-05

1.36E-01

S_Shelf

TRIM6
9

TSS1500

NCOR2

Body

S_Shelf

6.47

1.520

2.57E-05

1.37E-01

PRIC28
5

5UTR

N_Shore

-3.47

0.818

2.67E-05

1.40E-01

RASA3

Body

N_Shelf

7.05

1.660

2.70E-05

1.40E-01

IFI44L

TSS1500

-1.54

0.364

2.72E-05

1.40E-01

42914828

LIPE

Body

Island

22.00

5.210

2.75E-05

1.40E-01

11

314493

IFITM1

Body

N_Shore

1.180

2.78E-05

1.40E-01

cg05362517

13

37393368

RFXAP

5UTR;1stExon

Island

3.260

2.92E-05

1.42E-01

cg21145248

5

1.430

2.94E-05

1.42E-01

6

1.77

0.419

2.95E-05

1.42E-01

cg26912671

1

SLC34
A1
MAP3
K4
PDE4B

6.04

cg07537655

17681667
9
16141561
2
66458803

-4.98
13.80

10.70

2.540

3.01E-05

1.42E-01

Body
Body
1stExon

S_Shelf

25

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

cg11905821

6

31770932

6

12330239
9
29692085

LSM2
CCDC8
8B
LMOD
2
HLA-F

cg06202053

11

64109021

cg13794687

7

cg23892836
cg15331332

6

29692111

cg15804432

15

cg09251764

17

cg20893717

7

cg08159663

Body

N_Shelf

11.80

2.800

3.05E-05

1.42E-01

Body

N_Shore

-5.84

1.390

3.09E-05

1.42E-01

6.73

1.600

3.11E-05

1.42E-01

Body
Body

Island

-3.19

0.759

3.12E-05

1.42E-01

HLA-F

Body

S_Shore

-3.53

0.840

3.12E-05

1.42E-01

64454965

PPIB

Body

Island

-4.27

1.020

3.15E-05

1.42E-01

XAF1

TSS200

-5.73

1.370

3.23E-05

1.44E-01

EPO

TSS1500

Island

13.80

3.290

3.26E-05

1.44E-01

16

6659070
10031819
0
57022486

TSS1500

N_Shore

3.29E-05

1.44E-01

19

32836659

1stExon;5UTR

Island

4.120

3.55E-05

1.54E-01

cg11791770

11

611791

3UTR

Island

-3.44
17.20
-6.52

0.821

cg10019429

NLRC5
ZNF50
7
PHRF1

1.560

3.64E-05

1.56E-01

cg11653134

2

S_Shore

-4.24

1.020

3.81E-05

1.61E-01

cg06981309

3

N_Shore

-1.96

0.471

3.84E-05

1.61E-01

cg07168939

8

-5.88

1.420

3.88E-05

1.61E-01

cg04611649

2

cg16297569

1

66805547
14626095
4
14376341
2
15268124
0
92952517

cg01518846

6

26246970

cg26852894

4

11157341

cg06811183
ch.10.130520
3R

3

48510438

10

63407435

cg12461141

11

5710654

cg13149600

21

43374220

cg12660813

1

3192343

cg24447788

19

cg13861758

9

cg09950208

10

795310
13814809
9
13084123
5

cg01482620

19

48835971

cg03634735

7

1992524

*FDR: False discovery
rate

PLSCR1

5UTR

PSCA

Body

ARL5A

5UTR

N_Shelf

7.42

1.790

4.04E-05

1.66E-01

GFI1
HIST1H
4G

TSS1500;TSS200

Island

2.020

4.16E-05

1.70E-01

1stExon

Island

-8.34
17.50
6.31

4.240

4.41E-05

1.74E-01

1.530

4.42E-05

1.74E-01

-8.23

2.000

4.42E-05

1.74E-01

-8.63

2.090

4.43E-05

1.74E-01

-3.40

0.829

4.79E-05

1.87E-01

SHISA5

TRIM2
2
C2CD2
PRDM
16

TMEM
143
MAD1
L1

3UTR

TSS1500
TSS1500

S_Shore

-9.35

2.280

4.83E-05

1.87E-01

Body

N_Shelf

7.28

1.780

4.96E-05

1.89E-01

N_Shore

11.30

2.760

5.02E-05

1.89E-01

N_Shelf

5.08

1.240

5.02E-05

1.89E-01

-4.99

1.220

5.24E-05

1.95E-01

3UTR

N_Shore

18.40

4.500

5.28E-05

1.95E-01

Body

S_Shore

6.19

1.520

5.37E-05

1.97E-01

403
404

26

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table S1: Differentially methylated regions between high and low fraity in training set

405

chr

start

end

value

area

Number
of CpG

p.value

fwer

Gene.Symbol

FDR

3

122281881

122281975

-0.068

0.203

3

2.30E-07

0.001

DTX3L,PARP9

1.03E-04

12

11700321

11700489

-0.054

0.162

3

1.61E-06

0.006

LINC01252

3.60E-04

1

79088769

79118191

-0.039

0.154

4

1.17E-05

0.049

IFI44,IFI44L

1.75E-03

21

42797588

42797847

-0.046

0.092

2

2.41E-05

0.081

MX1

2.68E-03

1

79085162

79085765

-0.034

0.168

5

2.99E-05

0.122

IFI44L

2.68E-03

11

319555

319718

-0.036

0.109

3

4.73E-05

0.166

IFITM3

2.80E-03

11

312518

313624

-0.023

0.230

10

4.89E-05

0.194

IFITM1

2.80E-03

11

314493

317767

-0.021

0.228

11

5.01E-05

0.195

IFITM1

2.80E-03

21

42798747

42799141

-0.041

0.083

2

5.95E-05

0.197

MX1

2.96E-03

CpG
cg00959259;
cg08122652;
cg22930808
cg06202470;
cg18232235;
cg19651115
cg00458211;
cg01079652;
cg05696877;
cg07107453
cg22862003;
cg26312951
cg00855901;
cg03607951;
cg06872964;
cg13304609;
cg17980508
cg20045320;
cg09122035;
cg17990365
cg01886988;
cg01971407;
cg04582010;
cg05432003;
cg09026253;
cg10552523;
cg11694510;
cg20566897;
cg22963452;
cg27032101
cg12047941;
cg15013527;
cg25050332;
cg27331665;
cg03038262;
cg08000731;
cg08275025;
cg16379091;
cg18434560;
cg21686213;
cg23570810
cg08924203;
cg21549285

27

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

406

List of abbreviations

407

AUC: Area Under Curve

408

CI: Confidence interval

409

DMR: differentially methylated region

410

DNA: Deoxyribonucleic acid

411

DNAm: DNA methylation

412

DAVID: Database for Annotation, Visualization and Integrated Discovery

413

EWAS: epigenome-wide association study

414

FDR: False discovery rate

415

FWER: Family-wise error rate

416

GLMNET: Lasso and Elastic-Net Regularized Generalized Linear Models

417

GO: Gene ontology

418

HIV: Human immunodeficiency virus

419

HM450K: Human Methylation 450K BeadChip

420

NK: Natural killer

421

PC: Principal component

422

QC: Quality control

423

SVM: Support Vector Machines

424

VACS: Veterans Aging Cohort Study

425

VACS index: Veterans Aging Cohort Study index

426

XGBoost: Extreme Gradient Boosting Tree

427
428

28

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

429

Declarations

430

Ethics approval and consent to participate

431

The study was approved by the committee of the Human Research Subject Protection

432

at Yale University and the Institutional Research Board Committee of the Connecticut

433

Veteran Healthcare System. All subjects provided written consents.

434

Availability of data and materials

435

Demographic and clinical variables and DNAm data for the VACS samples were

436

submitted to GEO dataset (GSE117861) and are available to the public. All codes for

437

analysis are also available upon a request to the corresponding author.

438

Competing interests

439

The authors declare that they have no competing interests.

440

Funding

441

The project was supported by the National Institute on Drug Abuse (R03DA039745,

442

R01DA038632, R01DA047063, R01DA047820) and the National Center for Post-

443

Traumatic Stress Disorder, USA.

444

Authorsâ€™ contributions

445

CS was responsible for data analysis and manuscript preparation. ACJ provided DNA

446

samples, clinical data, and contributed to manuscript preparation. XZ was responsible

447

for the bioinformatics data processing. VM involved clinical data collection and

448

manuscript preparation. DH and EJ contributed to analytical approach and the

449

manuscript preparation. KX was responsible for the study design, study protocol,

450

sample preparation, data analysis, interpretation of findings, and manuscript

451

preparation.

29

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

452

Acknowledgements

453

The authors appreciate the support of the Veteran Aging Study Cohort Biomarker Core

454

and Yale Center of Genomic Analysis.

455
456
457

30

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

458

References

459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499

1.
Kooij KW, Wit FW, Schouten J, van der Valk M, Godfried MH, Stolte IG, et al. HIV
infection is independently associated with frailty in middle-aged HIV type 1-infected individuals
compared with similar but uninfected controls. AIDS. 2016;30(2):241-50.
2.
Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: A
review. Eur J Intern Med. 2016;31:3-10.
3.
Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based
biomarkers in colorectal cancer: a systematic review. Biochimica et Biophysica Acta (BBA)Reviews on Cancer. 2016;1866(1):106-20.
4.
Teroganova N, Girshkin L, Suter CM, Green MJ. DNA methylation in peripheral tissue of
schizophrenia and bipolar disorder: a systematic review. BMC genetics. 2016;17(1):27.
5.
Bakusic J, Schaufeli W, Claes S, Godderis L. Stress, burnout and depression: A systematic
review on DNA methylation mechanisms. Journal of Psychosomatic Research. 2017;92:34-44.
6.
Li M, Dâ€™Arcy C, Li X, Zhang T, Joober R, Meng X. What do DNA methylation studies tell us
about depression? A systematic review. Translational psychiatry. 2019;9(1):68.
7.
Horvath S. DNA methylation age of human tissues and cell types. Genome biology.
2013;14(10):3156.
8.
Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
ageing. Nature Reviews Genetics. 2018:1.
9.
Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-wide
methylation profiles reveal quantitative views of human aging rates. Molecular cell.
2013;49(2):359-67.
10.
Liu C, Marioni RE, Hedman Ã…K, Pfeiffer L, Tsai P-C, Reynolds LM, et al. A DNA
methylation biomarker of alcohol consumption. Molecular psychiatry. 2018;23(2):422.
11.
Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related
differential DNA methylation: 27K discovery and replication. The American Journal of Human
Genetics. 2011;88(4):450-7.
12.
Gao X, Zhang Y, Breitling LP, Brenner H. Relationship of tobacco smoking and smokingrelated DNA methylation with epigenetic age acceleration. Oncotarget. 2016;7(30):46878-89.
13.
Joubert BR, HÃ¥berg SE, Nilsen RM, Wang X, Vollset SE, Murphy SK, et al. 450K
epigenome-wide scan identifies differential DNA methylation in newborns related to maternal
smoking during pregnancy. Environmental health perspectives. 2012;120(10):1425-31.
14.
Lee KW, Pausova Z. Cigarette smoking and DNA methylation. Frontiers in genetics.
2013;4:132.
15.
Zhang X, Hu Y, Aouizerat BE, Peng G, Marconi VC, Corley MJ, et al. Machine learning
selected smoking-associated DNA methylation signatures that predict HIV prognosis and
mortality. 2018;10(1):155.
16.
Zhang R, Miao Q, Wang C, Zhao R, Li W, Haile CN, et al. Genome-wide DNA methylation
analysis in alcohol dependence. Addiction biology. 2013;18(2):392-403.
17.
Kraiczy J, Nayak KM, Howell KJ, Ross A, Forbester J, Salvestrini C, et al. DNA methylation
defines regional identity of human intestinal epithelial organoids and undergoes dynamic
changes during development. Gut. 2019;68(1):49-61.

31

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541

18.
Nano J, Ghanbari M, Wang W, de Vries PS, Dhana K, Muka T, et al. Epigenome-Wide
Association Study Identifies Methylation Sites Associated With Liver Enzymes and Hepatic
Steatosis. Gastroenterology. 2017;153(4):1096-106.e2.
19.
Delpu Y, Cordelier P, Cho W, Torrisani J. DNA methylation and cancer diagnosis.
International journal of molecular sciences. 2013;14(7):15029-58.
20.
Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, et al. DNA
methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer
cell. 2010;17(1):13-27.
21.
Holm K, Hegardt C, Staaf J, Vallon-Christersson J, JÃ¶nsson G, Olsson H, et al. Molecular
subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast
cancer research. 2010;12(3):R36.
22.
Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nature
Reviews Genetics. 2019;20(2):109-27.
23.
Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer
therapy: erasing the roadmap to cancer. Nat Med. 2019;25(3):403-18.
24.
Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella Jr FJ, et al.
Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailtyrelated phenotype of men with or at risk for HIV infection. The Journal of infectious diseases.
2016;215(2):228-37.
25.
Zhang X, Justice AC, Hu Y, Wang Z, Zhao H, Wang G, et al. Epigenome-wide differential
DNA methylation between HIV-infected and uninfected individuals. Epigenetics.
2016;11(10):750-60.
26.
Chen J, Huang Y, Hui Q, Mathur R, Gwinn M, So-Armah K, et al. Epigenetic Associations
with Estimated Glomerular Filtration Rate (eGFR) among Men with HIV Infection. Clin Infect Dis.
2019.
27.
Mathur R, Hui Q, Huang Y, Gwinn M, So-Armah K, Freiberg MS, et al. DNA Methylation
Markers of Type 2 Diabetes Mellitus Among Male Veterans With or Without Human
Immunodeficiency Virus Infection. J Infect Dis. 2019;219(12):1959-62.
28.
Breitling LP, Saum K-U, Perna L, SchÃ¶ttker B, Holleczek B, Brenner H. Frailty is associated
with the epigenetic clock but not with telomere length in a German cohort. Clinical Epigenetics.
2016;8(1):21.
29.
Sanchez-Conde M, Rodriguez-Centeno J, Dronda F, Lopez JC, Jimenez Z, Berenguer J, et
al. Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population.
Epigenomics. 2019;11(5):501-9.
30.
Horvath S, Levine AJ. HIV-1 infection accelerates age according to the epigenetic clock.
The Journal of infectious diseases. 2015;212(10):1563-73.
31.
Rickabaugh TM, Baxter RM, Sehl M, Sinsheimer JS, Hultin PM, Hultin LE, et al.
Acceleration of age-associated methylation patterns in HIV-1-infected adults. PloS one.
2015;10(3):e0119201.
32.
Gross AM, Jaeger PA, Kreisberg JF, Licon K, Jepsen KL, Khosroheidari M, et al.
Methylome-wide analysis of chronic HIV infection reveals five-year increase in biological age
and epigenetic targeting of HLA. Molecular cell. 2016;62(2):157-68.

32

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584

33.
Nelson KN, Hui Q, Rimland D, Xu K, Freiberg MS, Justice AC, et al. Identification of HIV
infection-related DNA methylation sites and advanced epigenetic aging in HIV-positive,
treatment-naive U.S. veterans. AIDS. 2017;31(4):571-5.
34.
Marioni RE, Shah S, McRae AF, Chen BH, Colicino E, Harris SE, et al. DNA methylation age
of blood predicts all-cause mortality in later life. Genome biology. 2015;16(1):25.
35.
Marioni RE, Harris SE, Shah S, McRae AF, von Zglinicki T, Martin-Ruiz C, et al. The
epigenetic clock and telomere length are independently associated with chronological age and
mortality. International journal of epidemiology. 2016;45(2):424-32.
36.
Perna L, Zhang Y, Mons U, Holleczek B, Saum K-U, Brenner H. Epigenetic age
acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort.
Clinical epigenetics. 2016;8(1):64.
37.
Christiansen L, Lenart A, Tan Q, Vaupel JW, Aviv A, McGue M, et al. DNA methylation
age is associated with mortality in a longitudinal Danish twin study. Aging Cell. 2016;15(1):14954.
38.
Fransquet PD, Wrigglesworth J, Woods RL, Ernst ME, Ryan J. The epigenetic clock as a
predictor of disease and mortality risk: a systematic review and meta-analysis. Clin Epigenetics.
2019;11(1):62.
39.
Zhang Y, Wilson R, Heiss J, Breitling LP, Saum K-U, SchÃ¶ttker B, et al. DNA methylation
signatures in peripheral blood strongly predict all-cause mortality. Nature communications.
2017;8:14617.
40.
Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally
generalizable risk index for mortality after one year of antiretroviral therapy. Aids.
2013;27(4):563-72.
41.
Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans
aging cohort study (VACS): overview and description. 2006;44(8 Suppl 2):S13.
42.
Lehne B, Drong AW, Loh M, Zhang W, Scott WR, Tan S-T, et al. A coherent approach for
analysis of the Illumina HumanMethylation450 BeadChip improves data quality and
performance in epigenome-wide association studies. 2015;16(1):37.
43.
Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al.
Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA
methylation microarrays. 2014;30(10):1363-9.
44.
Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, et al. Bump hunting to
identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol.
2012;41(1):200-9.
45.
Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, et al. The VACS index
predicts mortality in a young, healthy HIV population starting highly active antiretroviral
therapy. Journal of acquired immune deficiency syndromes (1999). 2014;65(2):226.
46.
Kuhn MJJoss. Building predictive models in R using the caret package. 2008;28(5):1-26.
47.
Hastie T, Tibshirani R, Friedman J, Franklin J. The elements of statistical learning: data
mining, inference and prediction. The Mathematical Intelligencer. 2005;27(2):83-5.
48.
Kotsiantis SB, Zaharakis I, Pintelas P. Supervised machine learning: A review of
classification techniques. Emerging artificial intelligence applications in computer engineering.
2007;160:3-24.

33

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600

49.
Chen T, Guestrin C, editors. Xgboost: A scalable tree boosting system. Proceedings of the
22nd acm sigkdd international conference on knowledge discovery and data mining; 2016:
ACM.
50.
Ogutu JO, Piepho H-P, Schulz-Streeck T. A comparison of random forests, boosting and
support vector machines for genomic selection. BMC Proc. 2011;5 Suppl 3(Suppl 3):S11-S.
51.
Brodersen KH, Ong CS, Stephan KE, Buhmann JM, editors. The balanced accuracy and its
posterior distribution. 2010 20th International Conference on Pattern Recognition; 2010: IEEE.
52.
Fresno C, FernÃ¡ndez EAJB. RDAVIDWebService: a versatile R interface to DAVID.
2013;29(21):2810-1.
53.
Justice AC, Modur SP, Tate JP, Althoff KN, Jacobson LP, Gebo KA, et al. Predictive
accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North
American cross cohort analysis. Journal of acquired immune deficiency syndromes (1999).
2013;62(2):149-63.
54.
O'Callaghan CA, Bell JIJIr. Structure and function of the human MHC class Ib molecules
HLA-E, HLA-F and HLA-G. 1998;163(1):129-38.

601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
34

medRxiv preprint doi: https://doi.org/10.1101/19010272; this version posted October 29, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633

35

Fi
gur
e3a

Fi
gur
e3b

Fi
gur
e3c

